| Budget Amount *help |
¥71,500,000 (Direct Cost: ¥71,500,000)
Fiscal Year 2009: ¥14,300,000 (Direct Cost: ¥14,300,000)
Fiscal Year 2008: ¥14,300,000 (Direct Cost: ¥14,300,000)
Fiscal Year 2007: ¥14,300,000 (Direct Cost: ¥14,300,000)
Fiscal Year 2006: ¥14,300,000 (Direct Cost: ¥14,300,000)
Fiscal Year 2005: ¥14,300,000 (Direct Cost: ¥14,300,000)
|
|---|
| Research Abstract |
We have tried to identify signaling or anti-apoptotic molecules, which have potential for novel therapeutic targets for leukemic treatment. We analyzed the function and molecular mechanisms in hematopoietic cell growth and leukemogenesis of Anamorsin, activated c-kit and Flt3, FIP1L1-PDGFR, and RUNX1 mutations. As a result, we found that these molecules might be candidates for novel molecular targets. In addition, we also identified several molecules whose mRNA expression is observed in leukemic stem cells, but not in normal hematopoietic stem cells.
|
